TOP Highlights From ASCO 2013

Breast cancer is less likely to recur in women previously treated for the disease if they take adjuvant tamoxifen for 10 years instead of 5 years.

Results from the phase 3 DECISION study showed that sorafenib significantly improved progression-free survival for patients with radioactive iodine–differentialted thyroid cancer.

Data presented at ASCO showed that several drugs in early-stage testing show promise. These drugs unleash the body’s immune system to attack cancer cells much as it attacks bacteria.

The results of several studies show new prospects for treating patients with advanced melanoma. Three novel strategies use the body’s immune system to attack melanomas.

PSA testing of healthy men has been the subject of much debate and clinical practice guideline recommendations from professional organizations and clinical panels in the United States are not necessarily in total agreement.